AMRN vs. ADCT, ANRO, ESPR, FBLG, ORGO, ATAI, NATR, NKTX, ANL, and RANI
Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include ADC Therapeutics (ADCT), Alto Neuroscience (ANRO), Esperion Therapeutics (ESPR), FibroBiologics (FBLG), Organogenesis (ORGO), Atai Life Sciences (ATAI), Nature's Sunshine Products (NATR), Nkarta (NKTX), Adlai Nortye (ANL), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical preparations" industry.
ADC Therapeutics (NYSE:ADCT) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 35.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Amarin had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Amarin and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.55 beat Amarin's score of 0.00 indicating that Amarin is being referred to more favorably in the news media.
Amarin has a net margin of -19.26% compared to Amarin's net margin of -344.15%. ADC Therapeutics' return on equity of -10.47% beat Amarin's return on equity.
ADC Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 72.81%. Amarin has a consensus target price of $1.08, indicating a potential upside of 23.82%. Given Amarin's stronger consensus rating and higher probable upside, research analysts plainly believe ADC Therapeutics is more favorable than Amarin.
ADC Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.
Amarin received 792 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 64.10% of users gave ADC Therapeutics an outperform vote.
Amarin has higher revenue and earnings than ADC Therapeutics. Amarin is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Amarin beats ADC Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Amarin News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
